CDC42 and neoplasm: Given that ARHGEF37 is associated with EC adherence and trans-endothelial migration via regulating Cdc42 activity, we speculated that a Cdc42 inhibitor would be potential therapeutic agent for ARHGEF37-mediated tumor cell invasion.